The Salt Lake City molecular-testing company just showed that demand is not the same thing as collected cash. Cancer and mental-health volumes still rise, yet the June quarter turned that volume into an eleven percent revenue decline because payers paid less, later, and sometimes not at all. Management cut full-year revenue guidance and suspended adjusted earnings before interest, tax, depreciation, and amortization targets while standing up an outside-led efficiency program called Ascend. The equity debate is whether collected price per test can be repaired before the cash account and a high-coupon term loan force a thinner company.
The Cancer Care Continuum still grew tests, and GeneSight kept adding clinicians, but hereditary-cancer average revenue per test fell hard enough to erase the volume gain. An eleven million revision to prior-period collection estimates sat inside that print, which is not a demand story. It is a statement that bills already issued are worth less than the company previously booked. Prenatal Health shrank on both volume and price, so the franchise that was supposed to stabilize the mix instead added to the hole.
Reported sales landed at $191 million against a year-ago print that was higher by a wide margin. Gross margin compressed, and adjusted operating expenses still rose because the first full quarter of a larger oncology sales force arrived at the same moment price cracked. Cash and equivalents ended the quarter at $115 million, with management citing about $190 million of available liquidity once undrawn capacity is counted. The next several quarters resolve a single question: does collected price per hereditary-cancer test stabilize, or does the company have to shrink itself to fit a smaller reimbursement envelope?